Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Cancer Genetics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1435605

The mutated in colorectal cancer (MCC) gene can serve as a potential biomarker of glioblastoma

Provisionally accepted
Huonggiang Nguyen Huonggiang Nguyen 1Uijin Juang Uijin Juang 1Suhwan Gwon Suhwan Gwon 1Woohyeong Jung Woohyeong Jung 1Qingzhi Huang Qingzhi Huang 1Soohyeon Lee Soohyeon Lee 1Beomwoo Lee Beomwoo Lee 1So Hee Kwon So Hee Kwon 2Jongsun Park Jongsun Park 1*Seon-Hwan Kim Seon-Hwan Kim 1*
  • 1 School of Medicine, Chungnam National University, Daejeon, Republic of Korea
  • 2 Yonsei University, Seoul, Seoul, Republic of Korea

The final, formatted version of the article will be published soon.

    The mutated in colorectal cancer (MCC) gene was initially identified as a candidate tumor suppressor gene in colorectal cancer, acting as a negative regulator of cell cycle progression.However, its functional roles in brain tumors, particularly glioblastoma, remains largely unexplored. This study reveals a significant association between MCC status and glioblastoma.In vitro analyses revealed elevated protein and mRNA levels of MCC in several glioblastoma cell lines (U118MG and T98G). Silencing MCC expression via siRNA-mediated knockdown resulted in increased proliferation and migration of these cell lines. Supporting these findings, analyses of The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and Genotype-Tissue Expression (GTEx) databases confirmed higher MCC expression in glioblastoma tumors than in normal brain tissue. Importantly, we observed that high MCC expression was associated with poor prognosis in glioblastoma patients, highlighting its potential role in disease progression. Additionally, this study identifies a nuclear localization of MCC in the glioblastoma cell line. Collectively, these findings indicate that MCC expression is significantly upregulated in glioblastoma and may play a role in its pathophysiology, warranting further investigation.

    Keywords: MCC, Glioblastoma, Cancer, biomarker, Brain

    Received: 20 May 2024; Accepted: 02 Sep 2024.

    Copyright: © 2024 Nguyen, Juang, Gwon, Jung, Huang, Lee, Lee, Kwon, Park and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jongsun Park, School of Medicine, Chungnam National University, Daejeon, Republic of Korea
    Seon-Hwan Kim, School of Medicine, Chungnam National University, Daejeon, Republic of Korea

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.